Emerg Infect Dis. 2022 Sep;28(9):1814-1823. doi: 10.3201/eid2809.220092.
We estimated costs of managing different forms of tuberculosis (TB) across Canada by conducting a retrospective chart review and cost assessment of patients treated for TB infection, drug-susceptible TB (DS TB), isoniazid-resistant TB, or multidrug-resistant TB (MDR TB) at 3 treatment centers. We included 90 patients each with TB infection and DS TB, 71 with isoniazid-resistant TB, and 62 with MDR TB. Median per-patient costs for TB infection (in 2020 Canadian dollars) were $804 (interquartile range [IQR] $587-$1,205), for DS TB $12,148 (IQR $4,388-$24,842), for isoniazid-resistant TB $19,319 (IQR $7,117-$41,318), and for MDR TB $119,014 (IQR $80,642-$164,015). Compared with costs for managing DS TB, costs were 11.1 (95% CI 9.1-14.3) times lower for TB infection, 1.7 (95% CI 1.3-2.1) times higher for isoniazid-resistant TB, and 8.1 (95% CI 6.1-10.6) times higher for MDR TB. Broadened TB infection treatment could avert high costs associated with managing TB disease.
我们通过对 3 家治疗中心治疗结核感染、药物敏感性结核(DS TB)、异烟肼耐药结核和耐多药结核(MDR TB)的患者进行回顾性图表审查和成本评估,估算了加拿大不同形式结核(TB)管理成本。我们纳入了 90 例结核感染和 DS TB 患者、71 例异烟肼耐药 TB 患者和 62 例 MDR TB 患者。结核感染(2020 加元)每位患者的平均费用为 804 加元(四分位距[IQR]为 587-1205 加元),DS TB 为 12148 加元(IQR 为 4388-24842 加元),异烟肼耐药 TB 为 19319 加元(IQR 为 7117-41318 加元),MDR TB 为 119014 加元(IQR 为 80642-164015 加元)。与管理 DS TB 的成本相比,结核感染的成本低 11.1 倍(95%CI 9.1-14.3),异烟肼耐药 TB 的成本高 1.7 倍(95%CI 1.3-2.1),MDR TB 的成本高 8.1 倍(95%CI 6.1-10.6)。扩大结核感染治疗范围可能避免管理结核疾病相关的高额成本。